Cellenkos, Inc.的封面图片
Cellenkos, Inc.

Cellenkos, Inc.

生物技术

Houston,Texas 1,130 位关注者

Developing off-the-shelf T regulatory (Treg) cell therapies for rare inflammatory diseases and autoimmune disorders.

关于我们

Cellenkos is a clinical stage biotechnology company developing allogeneic, off-the-shelf immune T regulatory (Treg) cell therapy products to offer anti-inflammatory effects and long-lasting immune modulation to address inflammatory and autoimmune diseases. Our CRANE® Platform allows for selection and enrichment of a subset of umbilical cord blood-derived Tregs tailed to a specific disease and supports our robust pipeline spanning rare autoimmune blood disorders, oncology, neuro-degenerative diseases and inflammatory pulmonary disease. Our Treg cell therapies do not require HLA matching, can be manufactured quickly and administered in an outpatient setting. Cellenkos was founded with the licensing of a proprietary umbilical cord blood T-Regulatory (Tregs) cell therapy platform from MD Anderson Cancer Center.

网站
http://cellenkosinc.com
所属行业
生物技术
规模
11-50 人
总部
Houston,Texas
类型
合营企业

地点

Cellenkos, Inc.员工

动态

相似主页

查看职位

融资

Cellenkos, Inc. 共 1 轮

上一轮

A 轮

US$15,000,000.00

投资者

BVCF
Crunchbase 上查看更多信息